Home
NewsNewsINVO Fertility acquires Family Beginnings in a strategic move to expand its U.S. footprint and strengthen patient-centered reproductive care. The acquisition integrates advanced IVF and INVOcell services, reinforces operational growth, and ensures leadership continuity under Dr. James Donahue within INVO’s expanding clinical network.
Feb. 19, 2026 – INVO Fertility, a leader in expanding access to assisted reproductive technology, announced the successful closing of its acquisition of Family Beginnings, P.C. This finalization marks the completion of the strategic transaction first detailed in the company's previous announcement.
The acquisition of the Indiana-based clinic was executed according to the terms of the definitive purchase agreement, with INVO acquiring the non-clinical assets for a combined purchase price of $760,000, $1 million in revenue, and $0.2 million in net income for the nine months ending September 30, 2025. This performance accounted for nearly 18% of INVO’s total clinic revenue during that period.
INVO Fertility acquires Family Beginnings with a clear focus on maintaining the high standard of personalized, patient-first care for which the clinic is known. To ensure a seamless transition and continuity of care, James Donahue, M.D., the clinic’s REI and lab director, has entered into a multi-year agreement to continue leading operations. Dr. Donahue, recently recognized as a 2026 Castle Connolly Top Doctor, brings decades of expertise to the INVO network.
The clinic offers a comprehensive suite of reproductive services, including traditional IVF, ovulation induction, and intrauterine insemination. Notably, Family Beginnings was an early adopter of INVO’s proprietary INVOcell solution, an intravaginal culture (IVC) procedure that allows fertilization to take place in vivo within the woman’s body.
Steve Shum, CEO of INVO Fertility, highlighted the strategic importance of the deal, stating that it expands the company’s geographic footprint while advancing its mission to provide affordable, high-quality fertility care. The closing follows a period of "meaningful progress" for the company, as INVO continues to execute a growth strategy centered on both organic initiatives and targeted acquisitions.
By integrating Family Beginnings into its growing network of operational U.S. clinics, INVO Fertility aims to leverage its broader clinical resources and ongoing investment in advanced technologies to support patients through the emotional journey of reproductive treatment.
The Stork Foundation for Infertility received a record 1,076 grant applications in 2026, with data revealing that 85% of applicants have no fertility treatment coverage for the care they are pursuing. Average anticipated next treatment costs stand at 19,149 USD, with 39% having already spent more than 10,000 USD out of pocket.
Future Health, A Global Initiative by Abu Dhabi has launched the Future Health Digital Health Innovation Challenge 2026, inviting global innovators to develop AI, software, and connected technology solutions across fertility, population health, and well-being. Three finalists will share USD 105,000 at GITEX 2026, with selected solutions eligible for incubation and scale.
La Trobe University and GonGlobal have entered a strategic collaboration to develop and validate AI and digital twin technologies for ART and IVF. The partnership will build AI-driven fertility care tools, including cohort matching digital twins and deep-learning models, to predict pregnancy outcomes and support personalised clinical decision-making.
IVI Institute has announced the acquisition of The World Egg and Sperm Bank (TWESB), founded in 2004 and operating from Scottsdale, Arizona. The move expands access to reproductive solutions for patients and clinics across the United States and Australia, combining TWESB’s network of 500+ screened donors with IVI Institute’s global clinical and scientific infrastructure.
Doctors at NHS Lothian in Edinburgh have performed the UK’s first testicular tissue transplant, reimplanting tissue frozen before chemotherapy in a 19-year-old patient with a serious blood disorder. The testicular tissue transplant, only the second reported worldwide, could eventually give thousands of young boys a realistic path to future fatherhood.
Flora Fertility and Clue have announced the Flora Clue fertility partnership, connecting the first individually owned fertility insurance platform with the world’s leading women-led cycle tracking app. FLORA policyholders receive complimentary Clue Plus access, while Clue’s community of over 100 million members gains early exposure to proactive fertility financial planning.
The World Health Organization releases its first comprehensive, evidence-based global guideline for infertility prevention, diagnosis, and treatment. Addressing one in six people of reproductive age worldwide, the guideline emphasizes equity, human rights, and standardized interventions to improve access to fertility care globally.
